Update on the use of pramipexole in the treatment of Parkinson’s disease
Radu ConstantinescuDepartment of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, SwedenAbstract: Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson’s disease (PD). This review addresses the literature concerning p...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/17db5ca1eeb748cd82866c37b72f19e4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Radu ConstantinescuDepartment of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, SwedenAbstract: Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson’s disease (PD). This review addresses the literature concerning pramipexole’s efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances.Keywords: pramipexole, Parkinson’s disease, efficacy, adverse events |
|---|